Rapport Therapeutics, Inc. (RAPP): Total Assets
$512.43M
As of 2025-12-31
$458.98M
As of 2026-06-30
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $512.43M | +62.7% | 2026-03-10, Balance as of period end |
| 2024-12-31 | $314.93M | +102.6% | 2026-03-10, Balance as of period end |
| 2023-12-31 | $155.42M | n/a | 2025-03-11, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | 2025-12-31 | $512.43M | +62.7% |
| Rigel Pharmaceuticals Inc (RIGL) | 2025-12-31 | $513.59M | +213.2% |
| Ardelyx, Inc. (ARDX) | 2025-12-31 | $501.60M | +15.1% |
| Syndax Pharmaceuticals Inc (SNDX) | 2025-12-31 | $529.71M | -26.9% |
| Dianthus Therapeutics, Inc. (DNTH) | 2025-12-31 | $530.92M | +42.0% |
| Olema Pharmaceuticals, Inc. (OLMA) | 2025-12-31 | $533.43M | +18.3% |
| Vanda Pharmaceuticals Inc. (VNDA) | 2025-12-31 | $488.95M | -25.5% |
| Oruka Therapeutics, Inc. (ORKA) | 2025-12-31 | $488.62M | +23.4% |
| Theravance Biopharma, Inc. (TBPH) | 2025-12-31 | $485.57M | +37.1% |
Compare RAPP, RIGL, ARDX, SNDX side by side · Screen every company in Pharmaceutical Preparations ↗